Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial

Neal Shore, Karim Fizazi, Teuvo Tammela, Luz Murilo, Manuel Philco Salas, Paul Ouellette, Sergio Lago, Diogo Assed Bastos, G. Kenneth Jansz, Flavio Mavignier Carcano , Livia Andrade , Marc Pliskin, Nicolas Lazaretti, Larissa De Arruda, Jose Jaime Correa, Oana Petrenciuc, Christian Kappeler, Toni Sarapohja, Matthew R. Smith